OBIZUR: payments to doctors
Payments that named OBIZUR as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $11.8M
- Providers
- 70
- Transactions
- 153
- Average per transaction
- $77,160
The per-transaction average — $77,160 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 70 providers the average total is $168,650, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $9,771,221 | 82.8% |
| Shire North American Group Inc | $2,034,265 | 17.2% |